Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Simultaneous ETA & AT1 Receptor Antagonism on Endothelial Function & Vascular Stiffness in ANCA-associated Vasculitis (SPARsentan in VASCulitis - SPARVASC)

NCT05630612 is registered in ClinicalTrials.gov with University of Edinburgh as lead sponsor.

NCT NCT05630612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05630612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Simultaneous ETA & AT1 Receptor Antagonism on Endothelial Function & Vascular Stiffness in ANCA-associated Vasculitis (SPARsentan in VASCulitis - SPARVASC)
Lead sponsor
University of Edinburgh
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 8, 2022
Completion date
September 1, 2027
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, cardiovascular diseases, kidney diseases